StemBioSys

StemBioSys

Early Stage

The Next Evolution in Cell Culture

The Next Evolution in Cell Culture

Overview

Raised this Round: Raised: $36,192

Total Commitments ($USD)

Platform

StartEngine

Start Date

06/04/2024

Close Date

09/03/2024

Min. Goal
$15,000
Max. Goal
$3,000,000
Min. Investment

$300

Security Type

Equity - Preferred

SEC Filing Type

RegCF    Open SEC Filing

Price Per Share

$3.00

Pre-Money Valuation

$42,053,985

Year Founded

2012

Industry

Healthcare & Pharmaceuticals

Tech Sector

Biotech

Location

San Antonio, Texas

StemBioSys, with a valuation of $42.05 million, is raising funds on StartEngine. It is a biomedical company that uses advanced cell technologies to test drugs more efficiently and accurately without using animal models. StemBioSys is innovating drug testing with patented lab tools and allows the testing of new products with cultured human cells and not from embryos or animal models. The pioneering products of StemBioSys include CELLvo Atrial Cardiomyocytes and Matrix Plus, and are used in biopharmaceutical, academic, and government markets. Robert Allen Hutchens founded StemBioSys in June 2012. The current crowdfunding campaign has a minimum target of $15,000 and a maximum target of $3 million. The campaign proceeds will be used for marketing, research and development, manufacturing capabilities, and working capital.

Summary Profit and Loss Statement

FY 2023 FY 2022

Revenue

$550,450

$367,734

COGS

$0

$0

Tax

$0

$0

 

 

Net Income

$-1,537,261

$616,327

Summary Balance Sheet

FY 2023 FY 2022

Cash

$111,047

$50,372

Accounts Receivable

$21,212

$33,429

Total Assets

$2,938,750

$3,543,332

Short-Term Debt

$1,586,281

$277,410

Long-Term Debt

$405,497

$819,118

Total Liabilities

$1,991,778

$1,096,528

Financials as of: 06/04/2024
Create a free account today to gain access to KingsCrowd analytics.

Upgrade to gain access

Pay Monthly
Annually (Save 17%)

Edge

$25 /month
billed annually
Free portfolio tracking, data-driven ratings, AI analysis and reports
Plan Includes:
Everything in Free, plus
Company specific KingsCrowd ratings and analyst reports
Deal explorer and side-by-side comparison
Startup exit and failure tracking
Startup market filters and historical industry data
Advanced company search ( with ratings)
Get Edge Annual
Already a member? Log in here.
Founders: enhance your startup's credibility on KingsCrowd. Create an account to claim this raise page.
Add to portfolio
StemBioSys on StartEngine 2024
Platform: StartEngine
Security Type: Equity - Preferred
Valuation: $42,053,985
Price per Share: $3.00

Follow company

Follow StemBioSys on StartEngine 2024

Buy StemBioSys's Deal Report

StemBioSys Deal Report

Get KingsCrowd’s comprehensive report on StemBioSys including:

  • How our proprietary algorithm rates their current capital raise (1-5 stars)
  • Detailed price, market, team, differentiators, performance, and risk ratings
  • Whether StemBioSys is undervalued or overvalued
  • Scores on the founding team and key personnel's background and expertise

Buy the StemBioSys deal report for only $10!

Email address:
Looking to buy more than one deal report? Get unlimited reports by upgrading to Edge